Alnylam Pharmaceuticals (ALNY) Cash from Financing Activities (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Cash from Financing Activities for 18 consecutive years, with $36.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Financing Activities fell 53.35% year-over-year to $36.2 million; the trailing twelve-month figure through Jun 2026 stood at -$377.0 million (down 246.4% YoY), and the FY2025 full-year result was -$305.2 million, down 203.75% from the prior year.
• Cash from Financing Activities climbed to $36.2 million in Q2 2026 per ALNY's latest filing, from $15.7 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $297.0 million in Q3 2022 and bottomed at -$474.3 million in Q3 2025.
• Historically, Cash from Financing Activities has averaged $35.5 million across 5 years, with a median of $42.3 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities jumped 210.08% in 2024, then sank 561.55% in 2025.
• Over 5 years, Cash from Financing Activities stood at $63.4 million in 2022, then tumbled by 38.16% to $39.2 million in 2023, then dropped by 20.98% to $31.0 million in 2024, then surged by 46.2% to $45.3 million in 2025, then dropped by 20.04% to $36.2 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $36.2 million, $15.7 million, and $45.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.